US Patent

US10010530 — Carboxamide derivative and its diastereomers in stable crystalline form

Composition of Matter · Assigned to Orlon Corp · Expires 2036-01-28 · 10y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects stable crystalline forms of the Nubeqa active substance and methods for preparing these crystalline forms.

USPTO Abstract

The present disclosure relates to solid crystalline forms of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.

Drugs covered by this patent

Patent Metadata

Patent number
US10010530
Jurisdiction
US
Classification
Composition of Matter
Expires
2036-01-28
Drug substance claim
Yes
Drug product claim
No
Assignee
Orlon Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.